Journal article
Impact of Distinct Antiandrogen Exposures on the Plasma Metabolome in Feminizing Gender-affirming Hormone Therapy
R Shepherd, LM Angus, T Mansell, B Arman, BW Kim, K Lange, D Burgner, JA Kerr, K Pang, JD Zajac, R Saffery, A Cheung, B Novakovic
Journal of Clinical Endocrinology and Metabolism | ENDOCRINE SOC | Published : 2024
Abstract
Context: The plasma metabolome is a functional readout of metabolic activity and is associated with phenotypes exhibiting sexual dimorphism, such as cardiovascular disease. Sex hormones are thought to play a key role in driving sexual dimorphism. Objective: Gender-affirming hormone therapy (GAHT) is a cornerstone of transgender care, but longitudinal changes in the plasma metabolome with feminizing GAHT have not been described. Methods: Blood samples were collected at baseline and after 3 and 6 months of GAHT from transgender women (n = 53). Participants were randomized to different anti-androgens, cyproterone acetate or spironolactone. Nuclear magnetic resonance-based metabolomics was used ..
View full abstractRelated Projects (1)
Grants
Awarded by State Government of Victoria
Funding Acknowledgements
B.N., A.C., and D.B. are supported by the Australian National Health and Medical Research Council (NHMRC) Investigator Grants (1173314, 2008956, and 1175744, respectively). B.N. and A.C. are supported by the Allen Distinguished Investigator program, a Paul G. Allen Frontiers Group advised program of the Paul G. Allen Family Foundation. Murdoch Children's Research Institute is supported by the Victorian Government's Operational Infrastructure Program. L.M.A. is supported by an Australian Government Research and Training Program scholarship. Research reported in this publication was supported by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health under Award Number R21AI179004. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.